Nicht-invasive Verfahren zur Bestimmung der Leberfibrose in der klinischen Praxis

Zusammenfassung

Die Kenntnis des Leberfibrosestadiums ist für die Einschätzung von Prognose und Verlauf und zur Beurteilung der Therapieindikation bei Patienten mit chronischen Lebererkrankungen von Bedeutung. Die Leberbiopsie gilt immer noch als Referenzmethode zur Beurteilung des Leberfibrosestadiums. Allerdings ist die Leberbiopsie eine invasive Methode mit entsprechenden Risiken und Limitationen. In den letzten Jahren wurden vermehrt nicht invasive Methoden wie Serummarker und ultraschallbasierte Elastografie-Verfahren zur Beurteilung des Leberfibrosestadiums evaluiert. Die vorliegende Arbeit gibt eine Übersicht über den aktuellen Stand der Forschung und den Stellenwert der nicht invasiven Verfahren in der klinischen Praxis.

Abstract

Staging of the degree of liver fibrosis is important for the estimation of prognosis, surveillance and treatment decision in patients with chronic liver diseases. At present, liver biopsy is still the reference standard for the assessment of liver fibrosis. However, it is an invasive method with respective complications and limitations. Thus, non-invasive methods such as blood fibrosis markers and ultrasound-based elastography methods have been intensively evaluated for the assessment of liver fibrosis. The aim of the present article is to give an overview of research and clinical applicability of non-invasive methods in chronic liver disease.

Schlüsselwörter

Virushepatitis - Elastografie - Stiffness - Leberbiopsie - nicht invasive Diagnostik

Key words

viral hepatitis - elastography - stiffness - liver biopsy - non-invasive diagnostics

• Literatur

• 1 Zeuzem S. Standard treatment of acute and chronic hepatitis C. Z Gastroenterol 2004; 42: 714-719
• 2 Fleig WE, Krummenerl P, Lesske J et al. Diagnosis, progression and therapy of hepatitis C virus infection as well as viral infection in children and adolescents – results of an evidenced based consensus conference of the German Society for Alimentary Metabolic Disorders and and in cooperation with the Hepatitis Competence Network. Z Gastroenterol 2004; 42: 703-704
• 3 Fleig WE, Krummener P, Lesske J. Criteria for the definition of acute and chronic hepatitis C. Z Gastroenterol 2004; 42: 707-713
• 4 National Institutes of Health Consensus Development Conference Statement. Management of hepatitis C 2002 (June 10-12, 2002). Hepatology 2002; 36: S3-S20
• 5 Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500
• 6 Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: redults of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000; 32: 477-481
• 7 Castera L, Negre I, Samii K et al. Pain experienced during percutaneous liver biopsy. Hepatology 1999; 30: 1529-1530
• 8 Froehlich F, Lamy O, Fried M et al. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993; 38: 1480-1484
• 9 Lindor KD, Bru C, Jorgensen RA et al. The role of ultrasonography and automatic-needle biopsy in outpatient percutaneous liver biopsy. Hepatology 1996; 23: 1079-1083
• 10 Perrault J, McGill DB, Ott BJ et al. Liver biopsy: complications in 1000 inpatients and outpatients. Gastroenterology 1978; 74: 103-106
• 11 Bedossa P, Dargere D, Paradise V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-1457
• 12 Bedossa P, Poynard T, Naveau S et al. Observer variation in assessment of liver biopsies of alcoholic patients. Alcohol Clin Exp Res 1988; 12: 173-178
• 13 Maharaj B, Maharaj RJ, Leary WP et al. Sampling variability and its influence on the diagnostic yield of percutaneous needle biopsy of the liver. Lancet 1986; 1: 523-525
• 14 Regev A, Berho M, Jeffers LJ et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-2618
• 15 Pilette C, Rousselet MC, Bedossa P et al. Histopathological evaluation of liver fibrosis: quantitative image analysis vs. semi-quantitative scores. Comparison with serum markers. J Hepatol 1998; 28: 439-446
• 16 Westin J, Lagging LM, Wejstal R et al. Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999; 19: 183-187
• 17 Baunsgaard P, Sanchez GC, Lundborg CJ. The variation of pathological changes in the liver evaluated by double biopsies. Acta Pathol Microbiol Scand [A] 1979; 87: 51-57
• 18 Soloway RD, Baggenstoss AH, Schoenfield LJ et al. Observer error and sampling variability tested in evaluation of hepatitis and cirrhosis by liver biopsy. Am J Dig Dis 1971; 16: 1082-1086
• 19 Poynard T, Munteanu M, Imbert-Bismut F et al. Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004; 50: 1344-1355
• 20 Imbert-Bismut F, Messous D, Thibaut V et al. Intra-laboratory analytical vaiability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors. Clin Chem Lab Med 2004; 42: 323-333
• 21 Cales P, Veillon P, Konate A et al. Reproducibility of blood tests of liver fibrosis in clinical practice. Clin Biochem 2008; 41: 10-18
• 22 Poynard T, Imbert-Bismut F, Munteanu M et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8
• 23 Castera L, Foucher J, Bernard PH et al. Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. Hepatology 2010; 51: 828-835
• 24 Friedrich-Rust M, Wunder K, Kriener S et al. Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009; 252: 595-604
• 25 Toshima T, Shirabe K, Takeishi K et al. New method for assessing liver fibrosis based on acoustic radiation force impulse: a special reference to the difference between right and left liver. J Gastroenterol 2011; 46: 705-711
• 26 Sporea I, Sirli RL, Deleanu A et al. Acoustic radiation force impulse elastography as compared to transient elastography and liver biopsy in patients with chronic hepatopathies. Ultraschall in Med 2011; 32 (Suppl. 01) S46-S52
• 27 Friedrich-Rust M, Hadji-Hosseini H, Kriener S et al. Transient elastography with a new probe for obese patients for non-invasive staging of non-alcoholic steatohepatitis. Eur Radiol 2010; 20: 2390-2396
• 28 de Ledinghen V, Wong VW, Vergniol J et al. Diagnosis of liver fibrosis and cirrhosis using liver stiffness measurement: comparison between M and XL probe of FibroScan®. J Hepatol 2012; 56: 833-839
• 29 Myers RP, Pomier-Layrargues G, Kirsch R et al. Feasibility and diagnostic performance of the FibroScan XL probe for liver stiffness measurement in overweight and obese patients. Hepatology 2012; 55: 199-208
• 30 Fraquelli M, Rigamonti C, Casazza G et al. Etiology-related determinants of liver stiffness values in chronic viral hepatitis B or C. J Hepatol 2011; 54: 621-628
• 31 Coco B, Oliveri F, Maina AM et al. Transient elastography: a new surrogate marker of liver fibrosis influenced by major changes of transaminases. J Viral Hepat 2007; 14: 360-369
• 32 Arena U, Vizzutti F, Corti G et al. Acute viral hepatitis increases liver stiffness values measured by transient elastography. Hepatology 2008; 47: 380-384
• 33 Millonig G, Friedrich S, Adolf S et al. Liver stiffness is directly influenced by central venous pressure. J Hepatol 2010; 52: 206-210
• 34 Millonig G, Reimann FM, Friedrich S et al. Extrahepatic cholestasis increases liver stiffness (FibroScan) irrespective of fibrosis. Hepatology 2008; 48: 1718-1723
• 35 Kuroda H, Takikawa Y, Onodera M et al. Serial changes of liver stiffness measured by acoustic radiation force impulse imaging in acute liver failure: a case report. J Clin Ultrasound 2012; 40: 99-104
• 36 Lin ZH, Xin YN, Dong QJ et al. Performance of the aspartate aminotransferase-to-platelet ratio index for the staging of hepatitis C-related fibrosis: an updated meta-analysis. Hepatology 2011; 53: 726-736
• 37 Shaheen AA, Myers RP. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis C-related fibrosis: A systematic review. Hepatology 2007; 46: 912-921
• 38 Jin W, Lin Z, Xin Y et al. Diagnostic accuracy of the aspartate aminotransferase-to-platelet ratio index for the prediction of hepatitis B-related fibrosis: a leading meta-analysis. BMC Gastroenterol 2012; 12: 14
• 39 Lieber CS, Weiss DG, Morgan TR et al. Aspartate aminotransferase to platelet ratio index in patients with alcoholic liver fibrosis. Am J Gastroenterol 2006; 101: 1500-1508
• 40 Shaheen AA, Wan AF, Myers RP. FibroTest and FibroScan for the Prediction of Hepatitis C-Related Fibrosis: A Systematic Review of Diagnostic Test Accuracy. Am J Gastroenterol 2007; 102: 2589-2600
• 41 Poynard T, Morra R, Halfon P et al. Meta-analyses of Fibrotest diagnostic value in chronic liver disease. BMC Gastroenterol 2007; 7: 40
• 42 Shaheen AA, Myers RP. Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008; 9: 43-51
• 43 Leroy V, Halfon P, Bacq Y et al. Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008; 41: 1368-1376
• 44 Degos F, Perez P, Roche B et al. Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: a multicenter prospective study (the FIBROSTIC study). J Hepatol 2010; 53: 1013-1021
• 45 Zarski JP, Sturm N, Guechot J et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56: 55-62
• 46 Sebastiani G, Castera L, Halfon P et al. The impact of liver disease aetiology and the stages of hepatic fibrosis on the performance of non-invasive fibrosis biomarkers: an international study of 2411 cases. Aliment Pharmacol Ther 2011; 34: 1202-1216
• 47 Cales P, Halfon P, Batisse D et al. Comparison of liver fibrosis blood tests developed for HCV with new specific tests in HIV/HCV co-infection. J Hepatol 2010; 53: 238-244
• 48 Sebastiani G, Halfon P, Castera L et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49: 1821-1827
• 49 Sebastiani G, Halfon P, Castera L et al. Comparison of three algorithms of non-invasive markers of fibrosis in chronic hepatitis C. Aliment Pharmacol Ther 2012; 35: 92-104
• 50 Bourliere M, Penaranda G, Renou C et al. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006; 13: 659-670
• 51 Leroy V, Hilleret MN, Sturm N et al. Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 775-782
• 52 Aube C, Oberti F, Korali N et al. Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999; 30: 471-478
• 53 Bernatik T, Strobel D, Hahn EG et al. Doppler measurements: a surrogate marker of liver fibrosis?. Eur J Gastroenterol Hepatol 2002; 14: 383-387
• 54 Colli A, Fraquelli M, Andreoletti M et al. Severe liver fibrosis or cirrhosis: accuracy of US for detection – analysis of 300 cases. Radiology 2003; 227: 89-94
• 55 Dietrich CF, Lee JH, Gottschalk R et al. Hepatic and portal vein flow pattern in correlation with intrahepatic fat deposition and liver histology in patients with chronic hepatitis C. Am J Roentgenol 1998; 171: 437-443
• 56 Lim AKP, Taylor-Robinson SD, Patel N et al. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005; 54: 128-133
• 57 Lim AKP, Patel N, Eckersley R et al. Hepatic vein transit time of SonoVue: a comparative study with Levovist. Radiology 2006; 240: 130-135
• 58 Cobbold JF, Patel D, Fitzpatrick JA et al. Accuracy and reliability of microbubble ultrasound measurements for the non-invasive assessment of hepatic fibrosis in chronic hepatitis C. Hepatol Res 2012; 42: 515-522
• 59 Tang A, Kim TK, Heathcote J et al. Does hepatic vein transit time performed with contrast-enhanced ultrasound predict the severity of hepatic fibrosis?. Ultrasound Med Biol 2011; 37: 1963-1969
• 60 Talwalkar JA, Kurtz DM, Schoenleber SJ et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2007; 5: 1214-1220
• 61 Stebbing J, Farouk L, Panos G et al. A meta-analysis of transient elastography for the detection of hepatic fibrosis. J Clin Gastroenterol 2010; 44: 214-219
• 62 Friedrich-Rust M, Ong MF, Martens S et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134: 960-974
• 63 Tsochatzis EA, Gurusamy KS, Ntaoula S et al. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol 2011; 54: 650-659
• 64 Musso G, Gambino R, Cassader M et al. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease. Hepatology 2010; 52: 79-104
• 65 Nguyen-Khac E, Chatelain D, Tramier B et al. Assessment of asymptomatic liver fibrosis in alcoholic patients using fibroscan: prospective comparison with seven non-invasive laboratory tests. Aliment Pharmacol Ther 2008; 28: 1188-1198
• 66 Cardoso AC, Carvalho-Filho RJ, Stern C et al. Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. Liver Int 2012; 32: 612-621
• 67 Adebajo CO, Talwalkar JA, Poterucha JJ et al. Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis. Liver Transpl 2012; 18: 323-331
• 68 Friedrich-Rust M, Nierhoff J, Lupsor M et al. Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat 2012; 19: e212-e219
• 69 Rizzo L, Calvaruso V, Cacopardo B et al. Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatitis C. Am J Gastroenterol 2011; 106: 2112-2120
• 70 Yoneda M, Suzuki K, Kato S et al. Nonalcoholic fatty liver disease: US-based acoustic radiation force impulse elastography. Radiology 2010; 256: 640-647
• 71 Friedrich-Rust M, Romen D, Vermehren J et al. Acoustic radiation force impulse-imaging and transient elastography for non-invasive assessment of liver fibrosis and steatosis in NAFLD. Eur J Radiol 2012; 81: e325-e331
• 72 Crespo G, Fernandez-Varo G, Marino Z et al. ARFI, FibroScan, ELF, and their combinations in the assessment of liver fibrosis: A prospective study. J Hepatol 2012; 57: 281-287
• 73 Bavu E, Gennisson JL, Couade M et al. Noninvasive in vivo liver fibrosis evaluation using supersonic shear imaging: a clinical study on 113 hepatitis C virus patients. Ultrasound Med Biol 2011; 37: 1361-1373
• 74 Ferraioli G, Tinelli C, Dal BB et al. Accuracy of real-time shear wave elastography for assessing liver fibrosis in chronic hepatitis C: A pilot study. Hepatology 2012; , in press.
• 75 Friedrich-Rust M, Schwarz A, Ong M et al. Real-time tissue elastography versus FibroScan for noninvasive assessment of liver fibrosis in chronic liver disease. Ultraschall in Med 2009; 30: 478-484
• 76 Koizumi Y, Hirooka M, Kisaka Y et al. Liver fibrosis in patients with chronic hepatitis C: noninvasive diagnosis by means of real-time tissue elastography – establishment of the method for measurement. Radiology 2011; 258: 610-617
• 77 Ferraioli G, Tinelli C, Malfitano A et al. Performance of real-time strain elastography, transient elastography, and aspartate-to-platelet ratio index in the assessment of fibrosis in chronic hepatitis C. Am J Roentgenol 2012; 199: 19-25
• 78 Ochi H, Hirooka M, Koizumi Y et al. Real-time tissue elastography for evaluation of hepatic fibrosis and portal hypertension in nonalcoholic fatty liver diseases. Hepatology 2012; 56: 1271-1278
• 79 Wang QB, Zhu H, Liu HL et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology 2012; 56: 239-247
• 80 Motosugi U, Ichikawa T, Sou H et al. Multi-organ perfusion CT in the abdomen using a 320-detector row CT scanner: Preliminary results of perfusion changes in the liver, spleen, and pancreas of cirrhotic patients. Eur J Radiol 2012; 81: 2533-2537
• 81 Godfrey EM, Patterson AJ, Priest AN et al. A comparison of MR elastography and (31)P MR spectroscopy with histological staging of liver fibrosis. Eur Radiol 2012; 22: 2790-2797
• 82 Huwart L, Sempoux C, Vicaut E et al. Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis. Gastroenterology 2008; 135: 299-302
• 83 Wang QB, Zhu H, Liu HL et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology 2012; 56: 239-247
• 84 EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264
• 85 EASL clinical practical guidelines: management of alcoholic liver disease. J Hepatol 2012; 57: 399-420
• 86 Nguyen-Khac E, Capron D, Braillon A et al. The non-invasive diagnosis of cirrhosis using the Fibroscan must be performed with cause-specific stiffness cut-offs. Gut 2008; 57: 1630-1631
• 87 Chen YP, Liang XE, Dai L et al. Improving transient elastography performance for detecting hepatitis B cirrhosis. Dig Liver Dis 2012; 44: 61-66
• 88 Yoon KT, Lim SM, Park JY et al. Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci 2012; 57: 1682-1691
• 89 Zarski JP, Sturm N, Guechot J et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56: 55-62
• 90 Castera L, Sebastiani G, Le Bail B et al. Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C. J Hepatol 2010; 52: 191-198
• 91 Shiratori Y, Imazeki F, Moriyama M et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524
• 92 Poynard T, McHutchison J, Manns M et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-1313
• 93 Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751
• 94 Chang TT, Liaw YF, Wu SS et al. Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893
• 95 Martinez SM, Fernandez-Varo G, Gonzalez P et al. Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C. Aliment Pharmacol Ther 2011; 33: 138-148
• 96 Hezode C, Castera L, Roudot-Thoraval F et al. Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011; 34: 656-663
• 97 Fontana RJ, Bonkovsky HL, Naishadham D et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009; 7: 219-226
• 98 Poynard T, McHutchison J, Manns M et al. Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003; 38: 481-492
• 99 Poynard T, Imbert-Bismut F, Ratziu V et al. Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002; 9: 128-133
• 100 Ogawa E, Furusyo N, Toyoda K et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009; 83: 127-134
• 101 Vergniol J, Foucher J, Castera L et al. Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009; 16: 132-140
• 102 Lim SG, Cho SW, Lee YC et al. Changes in liver stiffness measurement during antiviral therapy in patients with chronic hepatitis B. Hepatogastroenterology 2011; 58: 539-545
• 103 Osakabe K, Ichino N, Nishikawa T et al. Reduction of liver stiffness by antiviral therapy in chronic hepatitis B. J Gastroenterol 2011; 46: 1324-1334
• 104 Enomoto M, Mori M, Ogawa T et al. Usefulness of transient elastography for assessment of liver fibrosis in chronic hepatitis B: Regression of liver stiffness during entecavir therapy. Hepatol Res 2010; 40: 853-861
• 105 Ogawa E, Furusyo N, Murata M et al. Longitudinal assessment of liver stiffness by transient elastography for chronic hepatitis B patients treated with nucleoside analog. Hepatol Res 2011; 41: 1178-1188
• 106 Fung J, Lai CL, Wong DK et al. Significant changes in liver stiffness measurements in patients with chronic hepatitis B: 3-year follow-up study. J Viral Hepat 2011; 18: e200-e205
• 107 Wong GL, Wong VW, Choi PC et al. On-treatment monitoring of liver fibrosis with transient elastography in chronic hepatitis B patients. Antivir Ther 2011; 16: 165-172
• 108 Poynard T, Ngo Y, Marcellin P et al. Impact of adefovir dipivoxil on liver fibrosis and activity assessed with biochemical markers (FibroTest-ActiTest) in patients infected by hepatitis B virus. J Viral Hepat 2009; 16: 203-213
• 109 Poynard T, Zoulim F, Ratziu V et al. Longitudinal assessment of histology surrogate markers (FibroTest-ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-1980
• 110 Sebastiani G, Tempesta D, Fattovich G et al. Prediction of oesophageal varices in hepatic cirrhosis by simple serum non-invasive markers: Results of a multicenter, large-scale study. J Hepatol 2010; 53: 630-638
• 111 Fontana RJ, Sanyal AJ, Ghany MG et al. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology 2010; 138: 2321-2331
• 112 Poynard T, Ngo Y, Perazzo H et al. Prognostic value of liver fibrosis biomarkers: a meta-analysis. Gastroenterol Hepatol (N Y) 2011; 7: 445-454
• 113 Vergniol J, Foucher J, Terrebonne E et al. Noninvasive tests for fibrosis and liver stiffness predict 5-year outcomes of patients with chronic hepatitis C. Gastroenterology 2011; 140: 1970-1979
• 114 Naveau S, Gaude G, Asnacios A et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49: 97-105
• 115 Parkes J, Roderick P, Harris S et al. Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease. Gut 2010; 59: 1245-1251
• 116 Nunes D, Fleming C, Offner G et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105: 1346-1353
• 117 Robic MA, Procopet B, Metivier S et al. Liver stiffness accurately predicts portal hypertension related complications in patients with chronic liver disease: a prospective study. J Hepatol 2011; 55: 1017-1024
• 118 Kim BK, Kim dY, Han KH et al. Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol 2011; 106: 1654-1662, 1730
• 119 Colecchia A, Montrone L, Scaioli E et al. Measurement of Spleen Stiffness to Evaluate Portal Hypertension and the Presence of Esophageal Varices in Patients with HCV-Related Cirrhosis. Gastroenterology 2012; 143: 646-654
• 120 Vermehren J, Polta A, Zimmermann O et al. Comparison of acoustic radiation force impulse imaging with transient elastography for the detection of complications in patients with cirrhosis. Liver Int 2012; 32: 852-858
• 121 Talwalkar JA, Yin M, Venkatesh S et al. Feasibility of in vivo MR elastographic splenic stiffness measurements in the assessment of portal hypertension. Am J Roentgenol 2009; 193: 122-127
• 122 Nedredal GI, Yin M, McKenzie T et al. Portal hypertension correlates with splenic stiffness as measured with MR elastography. J Magn Reson Imaging 2011; 34: 79-87
• 123 Masuzaki R, Tateishi R, Yoshida H et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-1961
• 124 Jung KS, Kim SU, Ahn SH et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53: 885-894
• 125 de Ledinghen V, Vergniol J, Gonzalez C et al. Screening for liver fibrosis by using FibroScan and FibroTest in patients with diabetes. Dig Liver Dis 2012; 44: 413-418
• 126 Laharie D, Seneschal J, Schaeverbeke T et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010; 53: 1035-1040
• 127 Vermehren J, Vermehren A, Mueller A et al. Assessment of liver fibrosis and associated risk factors in HIV-infected individuals using transient elastography and serum biomarkers. BMC Gastroenterol 2012; 12: 27
• 128 Poynard T, Lebray P, Ingiliz P et al. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest). BMC Gastroenterol 2010; 10: 40
• 129 Roulot D, Costes JL, Buyck JF et al. Transient elastography as a screeing tool for liver fibrosis and cirrhoisis in a community-based population aged over 45 years. Gut 2011; 60: 977-84